(Q51130038)

English

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

scientific article published on 19 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

Per Soelberg Sørensen

2

object named as

P S Sorensen

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

author name string

N Koch-Henriksen

1

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

K Bendtzen

3

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

E M Flachs

4

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

publication date

19 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

15

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

5

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

601-605

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Anti-IFN BAb and NAb antibodies: a minireview

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1352458508101946

21 January 2018

Identifiers

10.1177/1352458508101946

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 March 2018

http://europepmc.org/abstract/MED/19299439

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51130038&oldid=1248130121"